1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.03. | Cyteir Therapeutics, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 25.03. | Cyteir Therapeutics executive buys $503k in company stock | 2 | Investing.com | ||
| 20.03. | Cyteir Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Cyteir Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 07.03. | Cyteir Therapeutics to delist from Nasdaq | 1 | Investing.com | ||
| 07.03. | Cyteir Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Cyteir Therapeutics, Inc. Announces Timeline for Voluntarily Delisting from Nasdaq | 79 | Business Wire | LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's... ► Artikel lesen | |
| 27.12.23 | Cyteir Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.12.23 | Cyteir Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.11.23 | Cyteir Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.23 | Cyteir Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.05.23 | Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights | 171 | Business Wire | LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31,... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -1,27 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,100 | +34,80 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,862 | +2,34 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,710 | +4,46 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK |
WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,790 | +5,40 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,070 | +3,88 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,520 | -4,95 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 1,010 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,430 | +1,18 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,030 | +0,37 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,195 | +5,09 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | +2,50 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,460 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,590 | -3,00 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,920 | +3,03 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen CYTEIR THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,020 Euro und damit -2,27 % im Minus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
